141626-57-5

Basic information

• Product Name: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide
• Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide
• CAS NO: 141626-57-5
• Molecular Weight: 634.858
• Mol File: 141626-57-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide(141626-57-5)
• EPA Substance Registry System: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide(141626-57-5)

Safety Data

• Hazardous Substances Data: 141626-57-5(Hazardous Substances Data)

Usage

Uses

N-Mesyldronedarone is an impurity of Dronedarone (D679445, HCl); a drug used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.

Upstream product

• 500791-70-8 5-amino-2-n-butyl-3-[4-(3-di-n-butylamino propoxy)benzoyl]benzofuran bisoxalate 
• 124-63-0 methanesulfonyl chloride 
• 141644-91-9 (5-amino-2-butyl-benzofuran-3-yl)-[4-(3-dibutylamino-propoxy)-phenyl]-methanone 
• 100-07-2 4-methoxy-benzoyl chloride 
• 141627-42-1 (2-butyl-5-nitrobenzofuran-3-yl)(4-methoxyphenyl)methanone 
• 133238-87-6 2-(n-butyl)-5-nitrobenzofuran 
• 5445-19-2 methyl 2-bromohexanoate 
• 1323367-38-9 2-butyl-5-iodobenzofuran 
• 466677-82-7 2-butyl-5-methoxybenzo[b]furan 
• 1323367-35-6 5-fluoro-2-butylbenzofuran 
• 497225-66-8 2-n-butyl-5-bromo-benzofuran 
• 108920-07-6 2-(2-formyl-4-chlorophenoxy)hexanoic acid 
• 1323367-31-2 methyl 2-(4-chloro-2-formyl-phenoxy)hexanoate 
• 55877-57-1 2-butyl-5-chlorobenzo[b]furan 

Downstream Products

• 141626-36-0 dronedarone 

Relevant articles and documents

Identification and characterization of potential impurities of dronedarone hydrochloride

Six potential process related impurities were detected during the impurity profile study of an antiarrhythmic drug substance, Dronedarone (1). Simple high performance liquid chromatography and liquid chromatography-mass spectrometry methods were used for the detection of these process impurities. Based on the synthesis and spectral data (MS, IR, 1H NMR, 13C NMR, and DEPT), the structures of these impurities were characterized a s 5-amino-3-[4-(3-di-n-butylaminopropoxy)benzoyl]-2-n-butylbenzofuran (impurity I); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)-benzoyl)benzofuran-5-yl)-N- (methylsulfonyl)-methanesulfonamide (impurity II); N-(2-butyl-3-(4-(3- (dibutylamino)propoxy)benzoyl)benzofuran-5-yl)-1-chloromethanesulfonamide (impurity III); N-{2-propyl-3-[4-(3-dibutylaminopropoxy)benzoyl]benzofuran-5-yl} - methanesulfonamide (impurity IV); N-(2-butyl-3-(4-(3-(dibutylamino)propoxy) benzoyl)benzofuran-5-yl)-formamide (impurity V); and (2-butyl-5-((3- (dibutylamino)propyl)amino)benzofuran-3-yl)(4-(3- (dibutylamino)propoxy)phenyl) methanone (impurity VI). The synthesis and characterization of these impurities are discussed in detail.

PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES

The present invention provides several synthetic methods for preparing N-(2-butylbenzofuran-5-yl)-N-(methylsulfonyl)methanesulfonamide, a compound of formula (3), an intermediate in the preparation of Dronedarone. The present invention further provides a process for preparing Dronedarone, comprising the steps of converting 2-butyl-5-bis(methanesulfon)-amidobenzofuran of formula (3) to Dronedarone, wherein the 2-butyl-5-bis(methanesulfon)-amidobenzofuran of formula (3) is prepared by the processes of the present invention.